Lilly said its antibody cocktail reduced the risk of death and hospitalization in high-risk patients by 70%, while Regeneron said its cocktail prevents COVID-19 in people exposed to the coronavirus.
The company said initial data from an ongoing study in hospitalized COVID-19 patients requiring low-flow oxygen shows the antibody therapy is sufficiently effective to warrant continuing the trial.
